Impact of Choice of Tariff When Calculating Clinically Meaningful EQ ‐ 5D Scores in Metabolic Dysfunction‐Associated Steatohepatitis
Liver International · 2025
DOI: 10.1111/liv.70043 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Liver International, 2025. Verfasst von James Piercy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Adelphi Real World, Bollington, UK. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Quality of Life. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Madrigal Pharmaceuticals.
Abstract (Originalsprache)
Background & Aims Self‐reported health varies across countries, as populations attribute different degrees of value to EQ‐5D domains. Country‐specific EQ‐5D tariffs were developed to account for this but are not always stated in the literature. We aim to assess the reporting of EQ‐5D in the literature and the impact of applying country‐specific tariffs.
Methods
We reviewed literature‐reported EQ‐5D utilities for patients with metabolic dysfunction‐associated steatohepatitis versus real‐world EQ‐5D utilities from the Adelphi Real World Non‐alcoholic steatohepatitis Disease Specific Programme (DSP), a cross‐sectional survey in France, Germany, Italy, Spain, the United Kingdom and the United States. Matching‐adjusted indirect comparison analysis balanced DSP data with literature studies by age, sex, comorbidities and fibrosis stage. DSP utility scores generated using national tariffs were compared with literature utilities using weighted t tests.
Results
Ten studies with varying recruitment criteria, patient demographics and clinical characteristics were identified. Country‐specific tariffs were not used or not reported. EQ‐5D utilities varied, reflecting geographic, clinical and demographic characteristics. The comparison of literature and matched utilities derived using DSP data and five national tariffs revealed ≥ two comparisons for each study with a difference not exceeding the minimal clinically important difference versus the matched DSP value.
Conclusions
Literature‐reported EQ‐5D utilities vary considerably depending on study methodology and country‐specific EQ‐5D tariff, and even if stated may not always use the most appropriate tariff. This suggests a need for consistent use of country‐specific tariffs and sensitivity analyses confirming results and conclusions that include EQ‐5D‐based utility measurement to inform decision‐making by health authorities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Adelphi Real World, Bollington, UK.
- Madrigal Pharmaceuticals, Conshohocken, Pennsylvania, USA.
ORCID-Profile: James Piercy, Jesse Fishman, Victoria Higgins, James Pike
Förderung
- Madrigal Pharmaceuticals
Zitieren
APA
Piercy, J., Fishman, J., Higgins, V., & Pike, J. (2025). Impact of Choice of Tariff When Calculating Clinically Meaningful EQ ‐ 5D Scores in Metabolic Dysfunction‐Associated Steatohepatitis. Liver International. https://doi.org/10.1111/liv.70043
Vancouver
Piercy J, Fishman J, Higgins V, Pike J. Impact of Choice of Tariff When Calculating Clinically Meaningful EQ ‐ 5D Scores in Metabolic Dysfunction‐Associated Steatohepatitis. Liver International. 2025. doi:10.1111/liv.70043
BibTeX
@article{Piercy2025,
author = {Piercy, James and Fishman, Jesse and Higgins, Victoria and Pike, James},
title = {Impact of Choice of Tariff When Calculating Clinically Meaningful EQ ‐ 5D Scores in Metabolic Dysfunction‐Associated Steatohepatitis},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70043}
}
EUVIMED